Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit

Frances D. Buckley; Claire Arnold; Dawn Brass; Mark Catherwood; Mary Frances McMullin

doi:10.1007/s11845-023-03510-7

Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit

Frances D. Buckley, Claire Arnold, Dawn Brass, Mark Catherwood, Mary Frances McMullin (Lead / Corresponding author)

Undergraduate Medicine

Research output: Contribution to journal › Article › peer-review

49 Downloads (Pure)

Abstract

Background: Polycythaemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm, typically driven by acquired JAK2 mutation and characterised by elevated red cell mass and increased risk of thrombotic events. Patients are managed with phlebotomy to maintain haematocrit (Hct) < 0.45, and patients stratified as 'high risk' for thrombosis are additionally treated with cytoreductive agents to attain this target.

Study: This analysis of newly diagnosed JAK2 mutant PV patients (n = 50) over 2 years aimed to determine how effectively patients attained and maintained target Hct according to recommended practice.

Conclusions: We found that patients spent the majority of time in target Hct range. Findings are supportive of current management guidelines.

Original language	English
Pages (from-to)	833-836
Number of pages	4
Journal	Irish Journal of Medical Science
Volume	193
Early online date	8 Sept 2023
DOIs	https://doi.org/10.1007/s11845-023-03510-7
Publication status	Published - Apr 2024

Keywords

Haematology
Myeloproliferative neoplasms
Polycythaemia

Access to Document

10.1007/s11845-023-03510-7Licence: CC BY

Final published versionFinal published version, 555 KBLicence: CC BY

Cite this

@article{aa90d7a306cb49b8a1c993a28d3bde96,

title = "Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit",

abstract = "Background: Polycythaemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm, typically driven by acquired JAK2 mutation and characterised by elevated red cell mass and increased risk of thrombotic events. Patients are managed with phlebotomy to maintain haematocrit (Hct) < 0.45, and patients stratified as 'high risk' for thrombosis are additionally treated with cytoreductive agents to attain this target.Study: This analysis of newly diagnosed JAK2 mutant PV patients (n = 50) over 2 years aimed to determine how effectively patients attained and maintained target Hct according to recommended practice.Conclusions: We found that patients spent the majority of time in target Hct range. Findings are supportive of current management guidelines.",

keywords = "Haematology, Myeloproliferative neoplasms, Polycythaemia",

author = "Buckley, {Frances D.} and Claire Arnold and Dawn Brass and Mark Catherwood and McMullin, {Mary Frances}",

note = "Copyright: {\textcopyright} 2023. The Author(s).",

year = "2024",

month = apr,

doi = "10.1007/s11845-023-03510-7",

language = "English",

volume = "193",

pages = "833--836",

journal = "Irish Journal of Medical Science",

issn = "0021-1265",

publisher = "Springer Science and Business Media Deutschland GmbH",

}

TY - JOUR

T1 - Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit

AU - Buckley, Frances D.

AU - Arnold, Claire

AU - Brass, Dawn

AU - Catherwood, Mark

AU - McMullin, Mary Frances

PY - 2024/4

Y1 - 2024/4

N2 - Background: Polycythaemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm, typically driven by acquired JAK2 mutation and characterised by elevated red cell mass and increased risk of thrombotic events. Patients are managed with phlebotomy to maintain haematocrit (Hct) < 0.45, and patients stratified as 'high risk' for thrombosis are additionally treated with cytoreductive agents to attain this target.Study: This analysis of newly diagnosed JAK2 mutant PV patients (n = 50) over 2 years aimed to determine how effectively patients attained and maintained target Hct according to recommended practice.Conclusions: We found that patients spent the majority of time in target Hct range. Findings are supportive of current management guidelines.

AB - Background: Polycythaemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm, typically driven by acquired JAK2 mutation and characterised by elevated red cell mass and increased risk of thrombotic events. Patients are managed with phlebotomy to maintain haematocrit (Hct) < 0.45, and patients stratified as 'high risk' for thrombosis are additionally treated with cytoreductive agents to attain this target.Study: This analysis of newly diagnosed JAK2 mutant PV patients (n = 50) over 2 years aimed to determine how effectively patients attained and maintained target Hct according to recommended practice.Conclusions: We found that patients spent the majority of time in target Hct range. Findings are supportive of current management guidelines.

KW - Haematology

KW - Myeloproliferative neoplasms

KW - Polycythaemia

UR - http://www.scopus.com/inward/record.url?scp=85170043248&partnerID=8YFLogxK

U2 - 10.1007/s11845-023-03510-7

DO - 10.1007/s11845-023-03510-7

M3 - Article

C2 - 37682452

SN - 0021-1265

VL - 193

SP - 833

EP - 836

JO - Irish Journal of Medical Science

JF - Irish Journal of Medical Science

ER -

Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this